Elezanumab(抗排斥性导向分子A单克隆抗体)在健康受试者和多发性硬化受试者中的1期评估
本研究在健康受试者和多发性硬化(MS)受试者中评估了抗排斥性导向分子A(RGMa)全人源单克隆抗体elezanumab(ABT-555)的安全性、耐受性、药代动力学和免疫原性。单中心首次人体单次递增剂量研究纳入47名健康男女,多中心多次递增剂量研究纳入20名MS成人受试者。结果显示未发现与研究药物相关的不良事件模式,脑脊液游离RGMa水平降低超过40%,药代动力学特征支持每月或每两个月给药高达1,800mg,并可选择3,600mg负荷剂量。
要点
- 健康受试者单次给药和MS受试者多次给药均未发现研究药物相关不良事件模式。
- 静脉输注后Tmax在4小时内,t1/2调和均值范围为18.6至67.7天。
- 脑脊液游离RGMa水平降低超过40%,支持中枢神经系统靶点结合。
核心结论
- Elezanumab的药代动力学特征支持每月或每两个月给药高达1,800mg,并可选择3,600mg负荷剂量。
- Elezanumab向脑脊液的分隔在单克隆抗体预期范围内;脑脊液游离RGMa水平降低表明其中枢神经系统靶点结合,静脉给药1,800mg时效果似达最大。
- 脑脊液IL-10(一种具有神经保护/神经修复特性的抗炎细胞因子)随暴露量增加,支持在MS受试者中潜在的通路调节。
研究设计与样本
- 单中心、首次人体、单次递增剂量(SAD)研究,评估elezanumab(50-1,600mg静脉给药和150mg皮下给药),纳入47名健康男女。
- 多中心多次递增剂量(MAD;NCT02601885)研究,评估elezanumab(150mg、600mg和1,800mg),纳入20名接受维持免疫调节治疗或无免疫调节治疗的MS成人男女。
主要发现
- SAD或MAD的elezanumab方案均未发现研究药物相关不良事件模式。
- 两项研究中,elezanumab静脉输注后Tmax均在4小时内,t1/2的调和均值范围为18.6至67.7天。
- 多次给药后,elezanumab的Cmax、曲线下面积和Ctrough呈剂量比例增加,并导致脑脊液elezanumab浓度呈剂量依赖性增加。
- 两项研究中elezanumab的脑脊液穿透率为0.1%至0.4%,脑脊液游离RGMa水平降低超过40%。
- 脑脊液白细胞介素-10(IL-10)和游离RGMa的变化显示剂量/暴露依赖性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study was undertaken to describe the safety, tolerability, pharmacokinetics, and immunogenicity of elezanumab (ABT-555), a fully human monoclonal antibody (mAb) directed against repulsive guidance molecule A (RGMa), in healthy and multiple sclerosis (MS) study participants. METHODS: The single-center, first-in-human, single ascending dose (SAD) study evaluated elezanumab (50-1,600mg intravenous [IV] and 150mg subcutaneous) in 47 healthy men and women. The multicenter multiple ascending dose (MAD; NCT02601885) study evaluated elezanumab (150mg, 600mg, and 1,800mg) in 20 adult men and women with MS, receiving either maintenance or no immunomodulatory treatment. RESULTS: No pattern of study drug-related adverse events was identified for either the SAD or MAD elezanumab regimens. Across both studies, the Tmax occurred within 4 hours of elezanumab IV infusion, and the harmonic mean of t1/2 ranged between 18.6 and 67.7 days. Following multiple dosing, elezanumab Cmax , area under the curve, and Ctrough increased dose-proportionally and resulted in dose-dependent increases in elezanumab cerebrospinal fluid (CSF) concentrations. Elezanumab CSF penetration was 0.1% to 0.4% across both studies, with CSF levels of free RGMa decreased by >40%. Changes in CSF interleukin-10 (IL-10) and free RGMa demonstrated dose/exposure-dependence. INTERPRETATION: The elezanumab pharmacokinetic profile supports monthly, or bimonthly, administration of up to 1,800mg with the option of a loading dose of 3,600mg. Elezanumab partitioning into CSF is within the range expected for mAbs. Reduced CSF levels of free RGMa demonstrate central nervous system target binding of elezanumab with an apparent maximal effect at 1,800mg IV. Exposure-associated increases in CSF IL-10, an anti-inflammatory cytokine with neuroprotective/neurorestorative properties, support potential pathway modulation in MS participants. ANN NEUROL 2023;93:285-296.
引用
- Kalluri HV, Rosebraugh MR, Misko TP, et al. Phase 1 Evaluation of Elezanumab (Anti-Repulsive Guidance Molecule A Monoclonal Antibody) in Healthy and Multiple Sclerosis Participants. Ann Neurol. 2022. PMID: 36093738. doi:10.1002/ana.26503
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。